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PPAR-ALPHA: A NOVEL TARGET IN PANCREATIC CANCER 
ALEXANDER MACH HUA 
ABSTRACT 
Background:  Current targeted therapies in pancreatic cancer have been ineffective. The 
tumor stroma, including intra- and peri-tumoral inflammation and fibrosis, is increasingly 
implicated in pancreatic cancer. Pancreatic cancer is characterized by a highly fibrotic 
tumor environment resulting in stromal resistance to chemotherapy. Peroxisome 
proliferator-activated receptor-alpha (PPARα), a ligand-activated nuclear 
receptor/transcription factor, is a negative regulator of inflammation. In PPARα deficient 
mice, stromal processes inhibit tumor growth, resulting in dormant tumors. The presence 
of PPARα in the tumor cells as well as in the host is necessary for unabated tumor 
growth. Objective: We hypothesized that blocking the PPARα pathway with a small 
molecule PPARα antagonist (NXT) may prevent pancreatic cancer progression by 
targeting tumor cells as well as non-neoplastic cells in the tumor microenvironment. 
Methods: Growth inhibitory activity of the PPARα antagonist was assessed in murine as 
well as human pancreatic tumor cell lines (Panc0H7 and BxPC3) and in a murine 
macrophage cell line (RAW 264.7). Cell viability was determined by trypan blue 
exclusion assay. AKT, P-AKT, PCNA, BAX, and p27 levels were analyzed by western 
blot analysis.  Cell cycle changes were detected by flow cytometry. Cellular senescence 
was determined by senescence-associated β-gal (SA-β-gal) staining. Results: The 
PPARα antagonist inhibited cell growth in macrophages and in pancreatic tumor cells as 
confirmed by reduced protein level expression of PCNA and activated AKT. Treatment 
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of the PPARα antagonist was non-cytotoxic to tumor cells. Inhibition of PPARα induced 
cell cycle arrest at G0/G1 in tumor cells and macrophages. The induction of cellular 
senescence was observed in pancreatic cancer cells. Interestingly, we observed a 
reduction in protein level expression of BAX, a marker for apoptosis, and p27, an 
inhibitor of the cell cycle. Conclusion: We now demonstrate that a PPARα antagonist 
exerts its anti-growth activity by inducing G0/G1 cell cycle arrest, thereby inducing 
cellular senescence without cell death. These findings provide a mechanism for the anti-
tumorigenic activity of PPARα inhibition, and the rationale to use PPARα antagonists as 
a novel therapeutic approach to pancreatic cancer. 
 
. 
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INTRODUCTION 
Biology and clinical aspects of pancreatic ductal adenocarcinoma 
Pancreatic cancer is a highly aggressive disease and is the 4
th
 leading cause of cancer-
related deaths in the United States. The one year survival rate is 20 %, and the five year 
survival rate is 6 % (Howlader et al., 2014). In 2014, in the United States alone, an 
estimated 45,440 patients were newly diagnosed with pancreatic cancer and 
approximately 39,590 patients died of the disease. Most patients are between 60 to 70 
years of age, and the disease is more common in men than in women. African Americans 
and Caucasians report the highest prevalence rate of pancreatic cancer compared to all 
other races (Howlader et al., 2014). The two most reported risk factors for pancreatic 
cancer are age and cigarette smoking (Li et al., 2004). Other associated risk factors 
include diabetes, chronic pancreatitis, family history, genetic syndromes, carcinogen 
exposure, and lifestyle factors such as a high fat diet (Yeo et al., 2002; Li et al., 2004). 
To date, an effective treatment for pancreatic cancer has yet to be established in the 
clinic.    
 
The pancreas is located in the abdominal cavity between the stomach and the spine, is 
approximately 6 inches long, and functions to aid in digestion and to regulate blood 
glucose levels (Bockman, 1993). The organ is made of an exocrine gland (releasing its 
products either inside or outside the body) and an endocrine gland (releasing its products 
directly into the bloodstream). The exocrine gland is comprised of acinar cells and ductal 
cells. Acinar cells synthesize, store, and secrete digestive enzymes into the pancreatic 
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duct to aid in breaking down proteins, nucleic acids, carbohydrates, and lipids in food. 
Ductal cells secrete mucous and bicarbonate to neutralize the acidic gastric chyme. The 
endocrine gland of the pancreas releases hormones into the blood stream that are 
important in maintaining glucose homeostasis. Endocrine cells are arranged in clusters 
called islet of Langerhans. Within each islet are alpha and beta cells that regulate blood 
glucose levels by releasing insulin and glucagon respectively, and delta cells that produce 
somatostatin to inhibit the release of pancreatic hormones (Barrett et al., 2010; Costanzo, 
2011).   
 
Exocrine tumors account for 95 % of all pancreatic cancer types (Öberg & Eriksson, 
2005; Tempero et al., 2010). Pancreatic ductal adenocarcinomas are considered to be 
aggressive, and tumors are rarely palpable due to the location of the pancreas. Symptoms 
will often present in later stages when the tumor has spread to neighboring tissues. 
Approximately 40 % of patients will demonstrate symptoms of distant metastases at the 
time of diagnosis (Li et al., 2015). Endocrine pancreatic tumors are uncommon, 
representing less than 5 % of all pancreatic cancer types (Öberg & Eriksson , 2005).   
 
The progression of the pathogenesis of pancreatic ductal adenocarcinoma (PDAC) arises 
from abnormal cells lining the pancreatic duct (precursor intraductal papillary lesions), 
which ultimately may progress into invasive PDAC if left untreated (Cubilla & 
Fitzgerald, 1976; Hruban, Wilentz, & Kern, 2000; Li et al., 2004). Intraductal papillary 
lesions, also referred to as pancreatic intraepithelial neoplasias (PaINs), can be 
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subdivided into four groups beginning from low grade PaIN-IA, PaIN-IB, PaIN-2, to 
high grade PaIN-3. PaIN staging is classified according to the increasing degrees of 
cellular changes, morphological alterations, and genetic mutation accumulation, as shown 
in Figure 1 (Bardeesy & DePinho, 2002; Vincent et al., 2011). Normal ductal cells are 
characterized by a low cuboidal shape and a single cell layer. PaIN-1A is characterized 
by elongated cells and mucin production.  PaIN-B is characterized by papillary 
architecture. PaIN-2 is characterized by nuclear abnormalities e.g. enlargement, loss of 
polarity, and crowding. PaIN-3 is characterized by budding into lumen, severe atypia, 
abnormal mitosis, and is most associated with the development of pancreatic ductal 
adenocarcinoma (Oliveira-Cunha, Siriwardena, & Byers,  2008). 
 
 
 
Figure 1 | PaIN progression model.  
Histological representation from normal (left) to high grade PaIN-3 (right) is associated with the accumulation of 
genetic mutations.   Figure adapted from Hruban et al., 2000. 
 
The development of PaINs from normal tissue to pancreatic cancer is the result of the 
overexpression of oncogenes and / or the loss of function of tumor suppressor genes (Li 
et al., 2004; Sakar, Banerjee, & Li, 2007). Oncogenes are “bad” genes that convert 
 4 
normal cells into cancerous cells, and are derived from normal genes called proto-
oncogenes that have been mutated or altered. The most common oncogene implicated in 
pancreatic cancer is the K-ras (Kristen rat sarcoma) proto-oncogene, and is considered 
the “signature” of pancreatic cancer. K-ras mutation is found in 85 % of all pancreatic 
cancers (Li et al., 2004; Oliveira-Cunha, Siriwardena, & Byers, 2008). Another 
protooncogene is Her/neu and its genetic mutation is present in 65 to 70 % of pancreatic 
cancers. Tumor suppressor genes function to slow down cell division and to protect 
against unabated cell proliferation. Mutation of tumor suppressor genes leads to 
unregulated cell growth (Yeo et al., 2002). The tumor suppressor gene, p16, is a critical 
regulator of the cell cycle at G1/S phase.  Approximately 27 to 98 % of pancreatic cancer 
patients have an inactivated p16 (Sakar, Banerjee, & Li, 2007). Other tumor suppressor 
genes that have been identified as genes commonly mutated in pancreatic cancer include 
p53 (40 - 75 %), p19 (27 - 82 %), and CDKN2B (27 - 48 %) (Li et al., 2004).   
 
 In early stages of the disease, patients with pancreatic cancer are often asymptomatic 
(DiMagno, 1999; Li et al., 2015). As the tumor spreads to affect surrounding tissues, 
common symptoms include muscle weakness (86 %), anorexia (83 %), weight loss (85 
%), and abdominal pain (79 %)  (Modelell, Guarner, & Malagelada, 1999; Vincent et al., 
2011). Jaundice (yellowing of the skin) is the most common sign observed as a result of 
tumor blockage of the common bile duct (Yeo et al., 2002; Porta et al., 2005). Early clues 
to identify at-risk patients include chronic pancreatitis, recent onset of diabetes mellitus 
in patients beyond the 6
th
 decade, intraductal papillary mucinous tumors, and familial 
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pancreatic cancer (DiMagno, 1999). The diagnosis of pancreatic adenocarcinoma can be 
confirmed by abdominal CT scans, tissue biopsy, and blood tests (Yeo et al., 2002; Li et 
al., 2015). 
                                                                                                                                                                                                                                                                                                                                                                                                 
Prognosis and long term survival of patients presenting with pancreatic ductal 
adenocarcinoma varies depending on tumor staging upon initial diagnosis (Snady et al., 
2000). To date, surgical resection of the tumors remains to be the closest curative 
treatment  (Snady  et al., 2000; Fernandez-del Castillo & Michael, 2015). However, only 
15 -20 % of patients have resectable tumors while the majority of patients (80 - 85 %) 
have unresectable or metastatic tumors at the time of diagnosis. The current standard of 
care for patients with advance pancreatic adenocarcinoma is the chemotherapeutic agent 
gemcitabine (Li et al., 2004; Gresham et al., 2014; Vincent et al., 2014). Gemcitabine, an 
anti-metabolite, prevents normal and tumorigenic cells from growing by specifically 
inhibiting DNA synthesis (Li et al., 2004). Gemcitabine is often used in combination with 
other chemotherapeutic agents in order to improve patient outcomes (Vincent et al., 
2011; Gresham et al., 2014). For example, in a clinical trial comparing gemcitabine plus 
nab-paclitaxel (Abraxane) versus gemcitabine alone, the combination resulted in an 
increased overall survival (8.5 months) compared to gemcitabine alone (6.7 months) 
(Von Hoff et al., 2013). Other agents that have been studied in combination with 
gemcitabine include oxaliplatin, capectiabine, cisplatin, and a four-drug regimen 
including FOLFIIRINOX (folinic acid, 5-fluorouacil, irinotecan, and oxaliplatin). 
Treatment of FOLFIRINOX and gemcitabine increased overall survival (11.1 months) 
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compared to gemcitabine alone (6.8 months), however, was associated with increased 
toxicity (Conroy et al., 2011). To date, there are no optimal therapeutic regimens 
established and despite extensive efforts, targeted therapies for pancreatic cancer have 
failed. Pancreatic cancer is characterized by a highly fibrotic environment that impedes 
the delivery of chemotherapy to the tumor cells resulting in chemoresistance (Feig et al., 
2012). Therefore, a better understanding of the molecular biology of pancreatic cancer is 
critical if we are to improve patient survival. 
 
PPAR (Peroxisome Proliferator-Activated Receptor) 
In the 1960s, a group in Switzerland observed that ethyl-α-(p-chlorophenoxy) isobutyrate 
(CPIB or Clofibrate), a known compound with lipid lowering (hypolipidaemic) properties 
in humans, resulted in the enlargement of the rat liver (hepatomegaly) when administered 
in the diet. More interestingly, the hepatomegaly was accompanied with the accumulation 
of what was then described as “microbodies” or peroxisomes (Figure 2). This observation 
of peroxisome proliferation was further confirmed by using potent hypolipadaemic 
analogs of clofibrate (Moody & Reddy, 1978). The relationship between the effect of 
hypolipidaemic drugs and the increase in production of peroxisomes was later confirmed 
with the discovery of two structurally unrelated compounds to clofibrate possessing 
hypolipidaemic properties (Reddy & Krishnakantha, 1975). This group of chemicals, 
capable of inducing massive formation of peroxisomes, became referred to as peroxisome 
proliferators  ( Lock, Mitchell, & Elcombe, 1989; Desvergne & Wahli, 1999). 
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Control Liver Cell CPIB-Treated Liver Cell 
  
Figure 2 | Peroxisome proliferation in CPIB-treated rat liver cell. 
Electron microscopy of a normal liver cell untreated (left) and treated with 500 mg/kg/day of CPIB (right) for 10 days.  
The liver cell treated with CPIB reveals an increase in the number of peroxisomes (peroxisomes are indicated by the 
red arrows). Adapted from Hess, Staubli, & Riess, 1965. 
 
 
Peroxisome Proliferation-Activator Receptors (PPARs) were first isolated from mouse 
cDNA in 1990, and they represent a separate group in the nuclear receptor superfamily 
(Issemann & Green, 1990). Other groups in the nuclear receptor superfamily include the 
retinoic acid receptors, thyroid hormone receptors, steroid receptors, and the orphan 
receptors (Desvergne & Wahli, 1999). Since its discovery in mouse, PPARs have been 
isolated in multiple species including rats, hamsters, and humans (Gottlicher et al., 1992; 
Sher et al., 1993; Aperlo et al., 1995). PPARs are a group of ligand-activated 
transcription factors (Kota, Huang, & Roufogalis, 2005), and play an important role in 
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lipid metabolism (Whali, Braissant, & Desvergne, 1995). PPARs are most commonly 
found in tissues with high activity of fatty acid oxidation, but are not just limited to the 
liver, heart, kidney, brown adipose tissue, muscle and small intestines (Pyper et al., 
2010).    
 
The PPAR family in humans consists of three isoforms: PPARα, PPARβ, PPARϒ (Kota, 
Huang, & Roufogalis, 2005). The PPAR gene consists of five distinguishable domains: 
A/B, C, D, E, and F, as shown in Figure 3 (Daynes & Jones, 2002). The A/B-domain at 
the N-terminus contains the activation function-1 (AF-1) region and serves as the 
independent ligand-binding domain. Phosphorylation at this site regulates the activation 
of PPAR (Burns & Vanden Heuvel, 2007). Following the A/B-domain is the DNA-
binding domain (C-domain) containing two zinc finger motifs capable of inserting itself 
into DNA at the peroxisome proliferator response element (PPRE) site (Desvergne & 
Wahli, 1999). The flexible hinge domain (D-domain) connects the DNA-binding domain 
to the ligand-binding domain (E-domain). The D-domain serves as a docking site for co-
repressor proteins in PPAR’s unliganded bound state (Kota, Huang, & Roufogalis, 2005; 
Pyper et al., 2010). The ligand-binding domain (E-domain) is responsible for ligand 
specificity and receptor dimerization with retinoic X receptor (RXR) (Daynes & Jones, 
2002). The ligand dependent activation domain, containing the activation function-2 (AF-
2 domain) region, serves to recruit co-activators to assist in gene transcription (Kota, 
Huang, & Roufogalis, 2005; Pyper et al., 2010). The most conserved regions found in 
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PPARs are the DNA-binding domain and the ligand-binding domain (Daynes et al., 
2002). 
 
Figure 3: Schematic representation of the functional domains of PPAR.   
PPAR isoforms in humans include PPARα, PPARβ, PPARϒ. The A/B-domain at the N-terminus contains the 
independent activation function-1 region while the F-domain at the C-terminus contains the dependent activation 
function-2 region. The C-domain contains the DNA-binding domain and is connected to the E-domain containing the 
ligand-binding domain by the hinge region (D-domain). The percentage represents the percent homology with respect 
to PPARα. Adapted from Daynes et al., 2002. 
 
 
Receptor activation occurs after the ligand binds to PPAR at the ligand-binding domain 
(Figure 4). In its unliganded state, PPAR is bound to its co-repressor complex N-
CoR/SMRT (co-repressor/silencing mediator for retinoid and thyroid hormone receptor) 
in the nucleus. Upon ligand-binding, PPAR undergoes a conformational change resulting 
in the dissociation of its co-repressor. Activation of PPAR allows PPAR to 
heterodimerize with retinoic X receptor (RXR) forming a PPAR:RXR heterodimer 
complex. Heterodimerization induces a second conformational change leading to the 
recruitment of the co-activator-acetyl transferase complex. PPAR:RXR attached to its co-
activator complex binds to the peroxisome proliferator response element (PPRE) in DNA. 
Co-activators, containing histone acetyltransferase activity, alter the chromatin structure 
by acetylating histone tails thereby regulating the transcription of PPAR target genes 
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(Daynes & Jones, 2002). About 10% of all human genes have the potential to be directly 
regulated by PPARs (Heinaniemi et al., 2007).  
 
Figure 4: Ligand induced activation of PPAR.   
In the unliganded bound state, PPARα is attached to its co-repressor to inhibit gene transcription. PPARα 
heterodimerizes with RXR after endogenous (fatty acid derivatives) or exogenous (drugs) ligand activation, and 
recruits co-activators to assist in regulating gene transcription.    
 
 
Endogenous ligands of PPARα include fatty acids and fatty acid derivatives (Desvergne 
& Wahli, 1999; Kota, Huang, & Roufogalis, 2005). In ligand binding studies in vitro, 
unsaturated long fatty acyl-CoAs as wells as unsaturated long chain fatty acids both 
exhibited high PPARα affinity (Hostetler et al., 2005). PPARα showed preferential 
binding to saturated long chain fatty acyl-CoAs, but not to saturated long chain fatty 
acids (Hostetler et al., 2005).   PPARα functions as a lipid sensor to maintain lipid 
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homeostasis. During high fatty acid states, PPARα  promotes the metabolism of fatty 
acids  (Reddy, 2004).   
 
Leukotriene B4 (LTB4) is an inflammatory mediator produced by inflammatory cells in 
response to infection or injury (Crooks & Stockley, 1998). Increased levels of LTB4 
promote the recruitment of innate immune cells to the site of infection, and ultimately 
prolong the inflammatory response duration. LTB4 activates PPARα through a negative 
feedback mechanism. At high concentrations, binding of LTB4 to PPARα stimulates fatty 
oxidation and LTB4 breakdown (Devchand et al., 1996).   
 
The fibrate class including fenofibrate, gemfibrozil, clofibrate are exogenous ligands of 
PPARα (Kota, Huang, & Roufogalis, 2005). By increasing fatty acid metabolism, these 
compounds have the ability to lower plasma triglyceride levels (Van Raalte et al., 2004). 
Fibrates are used in the clinic to treat hypercholesterolemia and to prevent metabolic and 
cardiovascular diseases (Van Raalte et al., 2004; Kota, Huang, & Roufogalis, 2005; 
Pyper et al., 2010).   
 
Inflammation: The link between PPAR and Cancer 
A connection between PPARs and cancer was first observed in 1975 after chronic 
administration of nafenopin, a potent PPARα agonist, caused hepatocellular carcinoma in 
mice (Reddy, Rao, & Moody, 1976). In 2002, it was demonstrated that PPARα knockout 
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mice resulted in resistance to ligand-activated tumor growth suggesting that PPARα plays 
an important role in cancer progression (Gonzalez, 2002).   
 
Interactions between tumor cells and non-malignant cells in the tissue stroma can feed 
into cell autonomous as well as non-cell autonomous pathways that can contribute to 
tumor growth (De Visser, Eichten, & Coussens, 2006; Chu et al., 2007). Inflammation is 
associated with pancreatic cancer, as pancreatitis is a known contributing factor for the 
development of pancreatic tumors (Guerra et al., 2007; Hagemann, Balkwill, & 
Lawrence, 2007). Pancreatic cancer can be characterized by a highly fibrotic tumor 
stroma formation consisting of non-neoplastic fibroblastic, vascular, and inflammatory 
cells, as well as other cell types that surround and interact with tumor cells (Chu et al., 
2007). The cells in the microenvironment can promote inflammation by releasing pro-
inflammatory cytokines, pro-angiogenic, and pro-lymphangiogenic growth factors (De 
Visser, Eichten, & Coussens, 2006; Hagemann, Balkwill, & Lawrence, 2007). Although 
inflammation has been demonstrated to exhibit pro-tumorigenic activity, it has recently 
been shown that inflammation can initiate the development of pancreatic tumors (Guerra 
et al., 2007). Embryonic mice with K-Ras oncogene mutation in acinar cells develop 
PanINs that progress into PDAC. However, adult mice with the same K-Ras oncogene 
mutation will not develop pancreatic tumors unless mild pancreatitis is induced (Guerra 
et al., 2007). Therefore, targeting inflammation in the tumor microenvironment may be a 
novel approach to prevent pancreatic cancer.   
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PPARα is a known negative regulator of inflammation and is necessary for unabated 
tumor growth (Devchand et al., 1996; Kaipainen et al., 2007). When PPARα negative 
tumors are injected into wildtype mice, a 41 % tumor growth inhibition is observed, and 
more dramatically, if PPARα is absent in both the tumor and the host, a 97 % tumor 
growth inhibition is observed, as shown in Figure 5 (Kaipainen et al., 2007). These 
results suggest that PPARα plays a key role in providing a favorable microenvironment 
for tumors to grow. Thus, PPARα antagonists could be novel therapy for pancreatic 
cancer. 
 
 
 
 
 
Figure 5 | Tumor growth is inhibited in absence of PPARα.   
Wildtype or PPARα negative tumors were subcutaneously injected into PPARα wildtype or deficient mice. PPARα 
negative tumors were created from isolating mouse embryonic fibroblast (MEF) from a PPARα knockout mouse and 
transformed with SV40 large T antigen and H-ras to obtain an isogenic tumorigenic cell line.   
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Specific Aim and Objectives 
Pancreatic ductal adenocarcinoma is a highly aggressive tumor, and is resistant to current 
chemotherapy and radiation treatments (Farrow, Albo, & Berger, 2008; Feig et al., 2012). 
Molecular targeted therapy provides an opportunity to customize cancer treatments in 
order to effectively treat patients and improve clinical outcomes. Peroxisome proliferator-
activated receptor (PPAR), a ligand-activated transcription factor, is a negative regulator 
of inflammation (Devchand et al., 1996). Genetic knockout of PPARα in mice resulted in 
suppression of tumor growth (Kaipainen et al., 2007). We hypothesized that blocking the 
PPARα pathway with a small molecule PPARα antagonist, NXT, may inhibit pancreatic 
cancer by targeting tumor cells as well as non-neoplastic cells in the tumor 
microenvironment. 
The present study addresses three main goals: 
1. To investigate the anti-growth activity of a PPARα antagonist 
2. To characterize the activity of PPARα inhibition on the cell cycle 
3. To elucidate the molecular mechanism by which a PPARα antagonist inhibits 
cell growth 
Our study aims to provide a potential mechanism for cell growth inhibition mediated by 
PPARα. This study will present evidence for the potential use of PPARα antagonists as a 
novel, therapeutic approach to complement current therapeutic regimens in the treatment 
of pancreatic cancer. 
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 METHODS 
Cell Lines 
Human pancreatic adenocarcinoma cell line, BxPC3, was obtained from American Type 
Culture Collection (ATCC Manassas, VA), and maintained in  Roswell Park Memorial 
Institute-1640 medium supplemented with 10 % fetal bovine serum (Life Technologies 
Grand Island, NY) and 200 mM L-glutamine, 10,000 units penicillin, and 10 mg/mL 
streptomycin (Sigma-Aldrich St Louis, MI) at 37 ºC and 10 % CO2. 
 
Murine pancreatic adenocarcinoma cell line, Panc0H7, was obtained from Diane 
Bielenberg Lab (Children’s Hosptial, Boston, MA) and maintained in Dulbecco’s 
Modified Eagle Medium (Life Technologies Grand Island, NY) supplemented with 10 % 
fetal bovine serum and 200 mM L-glutamine, 10,000 units penicillin, and 10 mg/mL 
streptomycin at 37 ºC and 10 % CO2. 
 
Murine leukaemic monocyte macrophage cell line, RAW 264.7, was obtained from 
American Type Culture Collection and maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM, ATCC 30-2002) (ATCC, Manassas, VA) supplemented with 10 % 
fetal bovine serum and 200 mM L-glutamine, 10,000 units penicillin, and 10 mg/mL 
streptomycin at 37 ºC and 5 % CO2 
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Observation of cell growth 
 
Cells (RAW 264.7, Panc0H7, and BxPC3) were plated in 10 cm cell culture plates (1 x 
10
6
 cells/plate) at room temperature. A day later, cells were treated with the PPARα 
antagonist (30 μM) or equal volume of DMSO (control). Differences in cell density in 
PPARα-treated cells were compared to control at 24 and 48 h. Images were captured 
under a bright-field compound microscope at a 10X magnification. 
 
 
Preparation of cytosolic and nuclear protein extracts for Western blot analysis 
Cells (BxPC3, Panc0H7, RAW 264.7) were plated in 6 wells cell culture plates (300,000 
– 500,000 cells/well) at room temperature. A day later cells were treated with the PPARα 
antagonist (15, 30 μM) or equal volume of DMSO for 48 h. Cell lysates were obtained by 
washing cells with cold Dulbecco’s phosphate buffered saline (Sigma-Aldrich St Louis, 
MI), and then lysed with cell lytic reagent (Sigma-Aldrich St Louis, MI) containing 
protease inhibitor (Roche South San Francisco, CA) and phosphatase inhibitor (Roche 
South San Francisco, CA) over ice. Cells were placed on Rocker I platform (Boekel 
Feasterville-Trevose, PA) for five minutes at 4 ºC. Cells were scraped off cell culture 
plate over ice using a cell scrapper. Cells plus lysis buffer was collected in 1.5ml 
Eppendorf microcentrifuge tube. Cells plus lysis buffer was centrifuged at 13.2 RPM for 
5 minutes in 4 ºC. Supernatant (lysate) was collected over ice and placed in new 1.5 ml 
Eppendorf microcentrifuge tube. Protein concentration in the supernatant was determined 
by the Bradford method using Bio-Rad Protein Assay reagent (BIO-RAD Herculues, CA) 
 17 
and bovine serum albumin (Cell Signaling Danvers, MA) (Zor et al., 1996). Samples 
were diluted with 6X reducing SDS sample buffer (Boston BioProducts Inc, Boston, 
MA). Samples were boiled for 5 minutes at 95 ºC, cooled over ice for 5 minutes, 
centrifuged at 13.2 RPM for 30 seconds, vortexed gently, and loaded into 10 - 12 % 
NuPage tris-acetate gels (Life Technologies Grand Island, NY., USA). Samples were 
allowed to migrate and separate for 1 h at 150 V, unlimited mAMPs until dye front 
reaches the bottom of the gel. Page ruler plus pre-stained protein ladder (BIO-RAD 
Herculues, CA) was used as reference molecular weight. Proteins were transferred onto a 
supported nitrocellulose membrane (BIO-RAD Herculues, CA) using semi-dry transfer 
unit (Hoefer Holliston, MA) at 15 V, unlimited mAmps for 1 - 2 h. After transfer was 
completed, membrane was stained with ponceau red (Sigma-Aldrich St Louis, MI) and 
transfer issues (bubbles, uneven loading) were noted. Ponceau red was washed away with 
distilled deionized water for 5 minutes on rocker platform (VWR Radnor, PA).  
Membrane was blocked with 5 % BSA in tris-buffered saline and 0.2 % tween 20 and 
incubated with primary antibodies overnight on red rotor (Hoefer Holliston, MA) at 4°C. 
Gels were washed with in tris-buffered saline and 0.2 % tween 20 on rocker I platform 
for 5 minutes, repeating the process four more times for a total of five washes, and 
incubated with the horseradish peroxidase-conjugated secondary antibodies for 1 hour at 
room temperature on rocker I platform. Membranes were washed with in tris-buffered 
saline and 0.2 % tween 20 for 5 minutes, repeating the process four more times for a total 
of five washes.  Signal was detected by enhanced chemiluminescence using supersignal 
west pico chemoluminescence substrate (LifeTechnologies Grand Island, NY) and 
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supersignal west femto chemiluminescent substrate (LifeTechnologies Grand Island, 
NY). The signal was detected on an autoradiography film 8 x 10 inches (MIDSCI St. 
Louis, MI). For re-probing, membrane was stripped by restore western blot stripping 
buffer (Thermo Scientific Waltham, MA) according to manufacturer’s instructions.   
 
 
Cell Cycle Analysis 
Cells were plated in 10 cm cell culture plate (1 x 10
6
 cells/well) at room temperature. A  
day later, cells were treated with the PPARα antagonist (30 μM) or equal volume of 
DMSO for 24 and 48 h. Cell cycle analysis was performed utilizing BD CycleTest plus 
DNA reagent kit (BD Biosciences San Jose, CA) according to manufacturer’s instruction 
using propidium iodide and processed for flow cytometry using BD LSR II flow 
cytometry machine (BD Biosciences San Jose, CA). Cell cycle profiles were obtained in 
ModFit LT. 
 
 
Cell Viability Assay 
Cells were divided into two groups: Washout group and No Washout group. The 
Washout group was divided into 3 subgroups (Control, PPARα antagonist, and Release) 
with two treatment periods and a washout procedure in between. The No Washout group 
was divided into 2 subgroups (Control and PPARα antagonist) with one treatment period 
and no washout. Cells were plated in 6 wells cell culture plates (50,000 cells/well) at 
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room temperature. A day later, cells were administered the first treatment for 24 h. In the 
Washout group, cells in the PPARα group received 30 µM of the PPARα antagonist and 
control group received equal volume of DMSO. Cells in the Release group received 30 
μM of the PPARα antagonist. In the No Washout group, cells received 30 μM of the 
PPARα antagonist or equal volume DMSO. After 24 hour incubation, all cells in the 
Washout group were washed three times with phosphate buffered solution and 
administered the second treatment for 48 h. Control cells and PPARα antagonist-treated 
cells received equal volume of DMSO or 30 μM of the PPARα antagonist respectively. 
The Release group was administered equal volume of DMSO. Control and PPARα 
antagonist cells in the No Washout group remained in their respective treatments for the 
remaining 48 h of the experiment for a total of 72 h. Shortly at the end of the second 
treatment, adherent and floating cells in each subgroup in the Washout and No Washout 
groups were collected separately into one single cell suspension.   
 
The viability of cells was assessed by Trypan blue exclusion assay (Life Technologies, 
Grand Island, NY) (Strober, 2001). Cells were diluted 1:1 using Trypan Blue and 10 μl of 
the sample was loaded onto a counting slide. The number of viable cells and the percent 
viability was determined using TC 20 automated cell counter (BIO-RAD Herculues, CA). 
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Senescence Assay 
 
Cells were plated on lab-trek chamber slides (15,000 cells/well) (Thermo Scientific 
Waltham, MA). A day later, cells were treated with the PPARα antagonist (30 μM) for 48 
h. Cells were stained for senescence-associated β-galactosidase activity utilizing 
senescence β-galactosidase staining kit according to manufacturer’s instructions (Cell 
Signaling Technologies Danvers, MA).   
 
 
Statistical Analysis 
 
Statistical Analyses were performed by Student’s t-test. The results were considered 
statistically significant at p< 0.05.   
 
 
Antibodies for Western Blot 
Specificity Species/isotype Concentration Company 
AKT Rabbit 1:1000 Cell Signaling 
Anti-Mouse Sheep 1:1000 GE Healthcare 
Anti-Mouse  Horse 1:1000 Cell Signaling 
Anti-Rabbit Donkey 1:1000 GE Healthcare 
Anti-Rabbit Goat 1:1000 Cell Signaling 
BAX Rabbit 1:1000 Cell Signaling 
P27 Kip  Rabbit 1:1000 Cell Signaling 
P-AKT (Ser473)  Rabbit 1:1000 Cell Signaling 
PCNA Mouse 1:1000 Cell Signaling 
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Software Programs 
 
Image J National Institutes of Health   
ModFit LT Verity Software House  
Prism GraphPad Software  
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RESULTS 
PPARα inhibition is associated with the reduction of cell density in macrophages  
and tumor cells. 
 
To determine whether the PPARα antagonist reduced cell growth, differences in cell 
density were observed in macrophages and tumor cells treated with the PPARα 
antagonist or control for 24 or 48 h. The PPARα antagonist reduced cell density in 
macrophages (RAW 264.7), and pancreatic tumor cells (Panc0H7 and BxPC3) as early as 
24 h after treatment (Figure 6, 7, & 8).  PPARα antagonist-treated cells were less dense at 
48 h after treatment, as observed by eye using a light microscope (Figure 6, 7, & 8). 
These results suggest that inhibition of PPARα leads to a reduction of cells after 48 h 
treatment.   
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Figure 6 | PPARα antagonist reduces cell growth in macrophages at 24 and 48 h.  
Macrophages (RAW 264.7) were plated in a 10 cm cell culture plate (1 x 106 cells/well) and treated with the PPARα 
antagonist (30 μM) or control for 24 or 48 h. Images were captured under a bright field compound microscope (10X).  
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Figure 7 | PPARα antagonist reduces cell growth in murine pancreatic tumor cells at 24 & 48 h.   
Murine pancreatic cancer cells (Panc0H7) were plated in 10 cm plate (1 x 106 cells/well) and treated with the PPARα 
antagonist (30 μM) or control for 48 h. Images were captured under a bright-field compound microscope (10X). 
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Figure 8 | PPARα antagonist reduces cell growth in human pancreatic tumor cells at 24 & 48 h.   
Human pancreatic cancer cells (BxPC3) were plated in 10 cm plate (1 x 106 cells/well) and treated with the PPARα 
antagonist or control for 48 h. Images were captured under a bright-field compound microscope (10X). 
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Treatment with the PPARα antagonist is non-cytotoxic to tumor cells. 
 
To examine whether the PPARα antagonist exhibited toxicity, cell viability was 
determined by Trypan blue exclusion assay. More specifically tumor cells were treated 
with the PPAR antagonist for 24 or 72 h (Figure 9). 
 
The Trypan blue exclusion assay is used to determine the number of live cells and dead 
cells in a cell suspension. Live cells have intact membranes that will pump out cationic 
dyes such as trypan blue, while dead cells will uptake the dye and become permanently 
stained. Live cells or viable cells will have a clear cytoplasm and will appear white, 
whereas non-viable cells or dead cells will have a blue cytoplasm and will appear blue 
(Srober, 2001). The percent viability of the cell suspension is calculated by dividing the 
number of viable cells (white) by the total number of cells (white + blue). The fraction is 
multiplied by 100 to obtain the percent viability. The percent cell death can then be 
calculated by subtracting 100 from the percent viability.   
 
Figure 10 shows the number of viable cells and percent cell death in each group. In the 
“washout group”, the number of viable cells was highest in the control (380 x 104 ± 15 x 
10
4
 cells/ml), lowest in the PPARα antagonist group (94 x 104 ± 6 x 104 cells/ml), and in 
the release group, the number viable cells was between either groups (276 x 10
4
 ± 11.7 x 
10
4
 cells/ml). The percent death in the control, PPARα antagonist group, and release 
group were 1.5 ± 0.2 %, 1.16 ± 0.2 %, and 1.5 ± 0.3 % respectively. These results suggest 
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that when the PPARα antagonist is removed from the growth media, tumor cells are able 
to resume growth suggesting that the PPARα antagonist is not killing the cells.   
 
In order to confirm the non-cytotoxic effect of the PPARα antagonist is not due to the 
washout itself, in which cells were washed with phosphate buffered saline three times to 
clear any residual PPARα antagonist found in the cell media, and thus removing floating 
dead cells, the number of viable cells and the percent death was obtained in the No 
washout group. In the No washout group, no washes are carried out throughout a 72 h 
treatment with the PPARα antagonist. The PPARα antagonist reduced the number of 
viable cells in the treated group (135 x 10
4
 ± 11 x 10
4
) compared to vehicle (343 x 10
4
 ± 
12 x 10
4 
cells/ml). The percentage of cell death in the control and the treated group were 
2 ± 0.4 %, 1.7 ± 0.6 % respectively. We confirmed that the growth inhibitory activity of 
the PPARα antagonist is not due to the result of the “washout.” 
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Figure 9 | Schematic representation to determine cytotoxicity of a PPARα antagonist.   
Timeline for the experimental procedure of the Washout and the No Washout groups.   
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Figure 10 | PPARα antagonist is not cytotoxic to tumor cells.   
Tumor cells were plated at in 6 wells cell culture plate (50,000 cells/well) and treated with the PPARα antagonist or 
control according to experimental design. Cytotoxicity was assessed by trypan blue exclusion assay. The data shown 
are representative of two independent experiments. The results are means +/- SEM (n=6); *p< 0.05 
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Antagonizing PPARα is associated with the reduction of P-AKT, AKT, BAX, PCNA 
in macrophages and tumor cells. 
 
To determine whether the PPARα antagonist regulates cell survival (P-AKT & AKT), 
apoptosis (BAX), and cell proliferation (PCNA), western blot analysis was performed on 
macrophages and pancreatic cancer cells treated with the PPARα antagonist or control for 
48 h.   
 
AKT, also called PKB, is an important signaling protein and is a marker for cell survival 
(Manning & Cantley, 2007; Pickhard et al., 2014). Activation of AKT requires the 
phosphorylation within the catalytic domain (Thr308) and within the hydrophobic motif 
(Ser473) (Tolker & Marmiroli, 2014). AKT exerts its activity by phosphorylating other 
downstream molecules, including mTOR (mammalian target of rapamycin) which is 
found to promote cell survival (Guertin et al., 2007). Treatment with the PPARα 
antagonist was associated with the reduction in phosphorylation of AKT as wells as the 
total levels of AKT in macrophages as well as in tumor cells, as shown in Figure 11. 
These results demonstrate that the PPARα antagonist may have a role in mediating the 
activation of the AKT signaling pathway, a marker for cell survival. 
 
Bax is a pro-apoptotic protein activated in the mitochondria extrinsic apoptotic pathway 
in response to cellular stress (Dewson & Kluck, 2009). Apoptosis is a process of 
programmed cell death, and naturally occurs in a number of cellular physiological 
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conditions such as in tissue remodeling and early embryogenesis (Ker, Wyllie, & Currie, 
1972; Penaloza et al., 2006). At the onset of apoptosis, BAX translocates from the 
cytosol to the mitochondrial outer membrane to increase the membrane’s permeability. 
The leakage of a pro-apoptotic molecule, cytochrome c, into the cytosol initiates caspase 
activation, which mediates apoptosis (Jeong & Seol, 2008). Cancer cells downregulate 
BAX to evade apoptosis. Surprisingly, treatment with the PPARα antagonist was 
associated with a reduction in BAX levels in macrophages and tumor cells (Figure. 11). 
The strongest reduction was observed at 30 μM of the PPARα antagonist in all three 
macrophage and tumor cell lines. These results suggest PPARα antagonism may play a 
role in the modulation of BAX expression, a marker for apoptosis.  
 
PCNA (Proliferating cell nuclear antigen) is a DNA replication accessory protein and is 
widely used as a marker of cell proliferation (Stoimevnov & Helleday, 2009; Wang, 
2014). PCNA acts as a sliding clamp forming a ring around DNA, and serves as a 
scaffold for specialized proteins involved in DNA replication (Stomevnov & Helleday, 
2009). Treatment with the PPARα antagonist reduced PCNA levels in RAW 264.7, 
Panc0H7 and BxPC3 cell lines (Figure. 11). The most potent reduction was observed at 
the 30 μM of the PPARα antagonist in both macrophages and tumor cells. These results 
suggest that the PPARα antagonist mediates the expression of PCNA, a marker for cell 
proliferation.   
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Figure 11 | PPARα inhibition reduces P-AKT, AKT, BAX, & PCNA expression in macrophages and tumor cells.  
Western blot analysis of protein lysate obtained from macrophages and tumor cells treated with the PPPARα antagonist 
or control for 48 h at the indicated concentration (15, 30 μM). Results are representative of at least three independent 
experiments with similar results. Quantifications are provided in Supplemental Figure 3, 4, & 5.   
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PPARα antagonist induces G0/G1cell cycle growth arrest in macrophages and tumor 
cells. 
To determine the role of PPARα on the cell cycle, flow cytometry was performed on 
macrophages (RAW264.7) and tumor cells (BxPC3) treated with the PPARα antagonist 
for 24 and 48 h, and 24 h, respectively. Cells were stained with propidium iodide (PI) and 
the cell cycle profiles were obtained by using fluorescence-activated cell sorting (Figure 
12 & 13).    
 
PI is a fluorochrome DNA binding dye. The amount of DNA can be determined by using 
a flow cytometer, in which a laser detects the stained cells, excites the dye, which then 
emits light. The emitted light is proportional to the amount of DNA in cells.  The cell 
cycle consists of several stages: G0/G1, S, G2, and M. G0/G1 is an intermediate stage 
between the end of the last cell division and the beginning of DNA replication. S-phase is 
the phase where DNA is replicated in order to allow cells to undergo division. G2 and M 
is characterized as a growth and mitotic phase. Cells in G2 have twice as much DNA and 
will proceed to divide during mitosis. At the end of G2/M, two daughter cells emerge 
(Luttmann, 2006).     
 
The cell cycle profile is obtained to determine the fraction of cells in the various stages of 
the cell cycle. The X-axis, “Channels (PI-A)” corresponds to the strength of the 
fluorescence signal, which is the intensity of the dye. In our analysis, we set the G0/G1 to 
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be at 50 fluorescence intensity (relative to a non-fluorescence cell). Because amount of PI 
binding is proportional to DNA content, we set G2/M to be at 100 fluorescence intensity.  
The S-phase corresponds to the intensity between G0/G1 and G2/M. An algorithm is 
employed by the analysis software to unbiasedly account for the overlap that occurs 
between the phases. The Y-axis corresponds to the number of cells in G0/G1, S, or G2/M. 
We set the flow cytometer to record 10,000 cells or events in each sample. Following the 
acquisition of the cell cycle profile, the data can be analyzed in a histogram where the X-
axis represents the phases of the cell cycle, and the Y-axis represents the percentage of 
events recorded in G0/G1, S, or G2/M. 
 
 
The fraction of cells in G0/G1 is increased in the PPARα antagonist-treated tumor cells 
and macrophages at 24 h and was accompanied with a decrease in the fraction of cells in 
S and G2/M, as shown in Figure 12 and 13. The fraction of cells in G0/G1 is increased at 
48 h compared to 24 h (63.8 ± 0.1 % to 75.1 % ± 0. 6%) in macrophages treated with the 
PPARα antagonist, (Figure 13 & 14). Therefore, antagonizing PPARα in macrophages 
(RAW 264.7) and tumor cells (BxPC3) resulted in cell cycle arrest at G0/G1.  
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Figure 12 | PPARα antagonist induces cell cycle arrest at G0/G1 in pancreatic tumor cells at 24 h.   
(A) Cell Cycle analysis by flow cytometry in BxPC3 cells treated with the PPARα antagonist (30 μM) or control for 24 
h. The X-axis corresponds to the fluorescence intensity at each channel, and the Y-axis corresponds to number of 
events at each channel. (B) Histogram showing the percentage of cells in each phase of the cell cycle. The results are 
means +/- SEM (n=2); *p< 0.05 
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Figure 13 | PPARα antagonist induces cell cycle arrest at G0/G1 in macrophages cells at 24 h.   
(A) Cell Cycle analysis by flow cytometry in RAW 264.7 cells treated with the PPARα antagonist (30 μM) or control 
for 24 h. The X-axis corresponds to the fluorescence intensity at each channel, and the Y-axis corresponds to number of 
events at each channel. (B) Histogram showing the percentage of cells in each phase of the cell cycle. The results are 
means +/- SEM (n=2); *p< 0.05 
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Figure 14 | PPARα antagonist induces cell cycle arrest at G0/G1 in macrophages at 48 h.   
(A) Cell Cycle analysis by flow cytometry in RAW 264.7 cells treated with the PPARα antagonist (30 μM) or control 
for 48 h. The X-axis corresponds to the fluorescence intensity at each channel, and the Y-axis corresponds to number of 
events at each channel. (B) Histogram showing the percentage of cells in each phase of the cell cycle. The results are 
means +/- SEM (n=2); *p< 0.05 
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Antagonizing PPARα associated with reduction p27 in tumor cells.  
 
To determine whether the PPARα antagonist modulates p27 protein expression, the 
expression of p27 was determined by Western blot analysis in tumor cells treated with the 
PPARα antagonist (15, 30 μM) or equal volume of DMSO for 48 h. 
 
p27 (KIP1) is a cyclin-dependent kinase inhibitor of the CDK2/cyclin E complex. 
Inhibition of CDK2/cyclin E prevents cell cycle progression, thus p27 acts as a negative 
regulator of the cell cycle at the G1/S phase (Bretones, Delgado, & Leon, 2014). In 
cancer, p27 is downregulated or impaired (Sgambato et al. 2000). Surprisingly, treatment 
of pancreatic cancer cells (Panc0H7) with the PPARα antagonist was associated with the 
reduction of p27 levels (Figure 15). The most potent reduction in p27 expression was 
observed at 30 μM of the PPARα antagonist. Therefore, inhibition of PPARα may play a 
role in regulating p27 activity.   
 
Figure 15 | PPARα antagonist inhibits expression of p27 in tumor cells.   
Western blot analysis of protein lysate obtained from human pancreatic cancer cells (Panc0H7) treated with the 
PPPARα antagonist or control for 48 h at the indicated concentrations (15, 30 μM). Results are representative of at least 
two independent experiments with similar results. Quantifications are provided in Supplemental Figure 4.   
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PPARα antagonist induces cellular senescence in pancreatic tumor cells. 
 
To determine whether the PPARα antagonist’s anti-growth activity is mediated by 
therapy-induced senescence, β-galactosidase activity was measured in pancreatic cancer 
cells (Panc0H7) treated with the PPARα antagonist for 48 h.   
 
Cellular senescence is defined as a state of stable exit from the cell cycle and an 
irreversible cell growth arrest in G0/G1 (Itahana, Campisi, & Dimri, 2007; Perez-
Mancera, Young, Narita, 2014). One biomarker used for detecting senescence in cells is 
β-galactosidase activity (Gary & Kindell, 2005). Enzyme activity is measured by staining 
cells with an artificial substrate X-gal (5-bromo-4-chloro-3-indolyl-beta 
galactopyranoside). β-galactosidase will catalyze the hydrolysis of X-gal, which produces 
a blue color in senescent cells (Gary & Kindell, 2005). Cells positive for senescence are 
stained blue while non-senescent cells are unstained.   
 
Treatment with the PPARα antagonist increased the number of Panc0H7 cells with SA-β-
gal activity (senescent associated β-galactosidase) compared to control (Figure 16). No or 
little SA-β-gal activity was observed in non-treated cells, whereas treated cells were 
stained blue. These results suggest a mechanism whereby the PPARα antagonist reduces 
cell growth by therapy-induced senescence.   
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Figure 16 | PPARα antagonist induces cellular senescence in pancreatic cancer cells.   
Tumor cells were plated in chamber slides (15,000 cells/well). SA-β-gal activity was measured in Panc0H7 cells treated 
with PPARα antagonist (30μM) for 48 h. Images were captured under a bright-field compound microscope (20X).   
 41 
 
DISCUSSION 
 
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor and is 
characterized by a highly fibrotic tumor environment resulting in stromal resistance to 
chemotherapy (Farrow, Albo, & Berger, 2008; Feig et al., 2012). Only 6% of patients 
diagnosed will survive more than five years (Howlander et al., 2014). Current 
approaches, such as surgery, radiation, chemotherapy, or combination therapies, have had 
little effect in long term survival outcome (Li et al., 2004; Lockhart, Rothenberg, & 
Berlin, 2005; Stathis & Moore, 2010). Thus, a better understanding of the molecular basis 
and progression of pancreatic cancer is needed in order to diagnose, treat, and prevent 
this disease.   
 
PPARα is a ligand-activated transcription factor that belongs to the nuclear receptor 
superfamily (Kota, Huang, & Roufogalis, 2005). In addition to its role in β-oxidation and 
lipid metabolism, PPARα activation is involved in regulating inflammation and ligand-
induced tumor growth (Reddy & Azarnoff, 1980; Devchand et al., 1996). Accordingly, 
PPARα knockout mice exhibited a prolonged inflammatory response and are resistant to 
the hepatocarcinogenic effect of PPARα agonists (Devchand et al., 1996; Peters, Cattley, 
& Gonzalez, 1997). More recently, PPARα activation has been observed with increased 
proliferation in breast cancer cells (Suchanek et al., 2002). Conversely, PPARα agonists 
also play an anti-tumorigenic role by inhibiting cancer progression of melanoma, 
endometrial, and fibroblast cancer cells (Grabacka et al., 2006; Saidi et al., 2006; Pozzi 
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& Capdevilla, 2008). Thus, despite our current knowledge of PPARα, whether PPARα 
promotes or inhibits cancer remains unclear (Panigrahy et al., 2008). This suggests the 
complexity of the receptor and its resulting biological, pleiotropic effects. Future studies 
will be necessary in order to clarify the role of PPARα in human cancer development.   
 
The tumor microenvironment plays a crucial role in promoting cancer progression 
(Farrow, Albo, & Berger, 2008). The active role of non-neoplastic cells including 
immune cells, fibroblasts, and other cell types can induce inflammation in the 
microenvironment and exacerbate tumor growth (Farrow, Albo, & Berger 2008). As a 
basis for this study, we have found the presence of PPARα in both the tumor and the host 
is necessary for tumor growth (Kaipainen et al., 2007). Although studies have 
demonstrated the anti-proliferative effects of PPARϒ activation in pancreatic cancer, the 
role of PPARα has been less characterized (Eibl, 2008). Our study is the first to evaluate 
the role of PPARα inhibition in pancreatic cancer. The aims of the present study were (1) 
to investigate the anti-growth activity of a PPARα antagonist, (2) to characterize the 
activity of PPARα inhibition on the cell cycle, and (3) to elucidate the molecular 
mechanism by which a PPARα antagonist inhibits cell growth. 
 
To elucidate the mechanism by which the PPARα antagonist inhibits cell growth, 
treatment with the PPARα antagonist in macrophages and pancreatic cancer cells reduced 
protein level expression of P-AKT, AKT, PNCA, and BAX (Figure 11). AKT is a marker 
for cell survival, and the protein exists in a complex with Hsp27. Heat shock proteins 
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(Hsp) are a group of molecular chaperons, and the interaction between Hsp27 and AKT is 
necessary for AKT to promote cell survival (Guo et al., 2009). PPARα antagonists may 
act by directly reducing the expression levels of Hsp27 or indirectly by disrupting the 
Hsp27/AKT interaction. Future studies will be needed to characterize expression levels of 
Hsp27 in PPARα antagonist-treated tumor cells and macrophages. Interestingly, we 
observed a decrease in BAX, a marker for apoptosis, thus suggesting that cells have 
prolonged survival. Recently it has been shown BAX may play a dual role by regulating 
cell proliferation as well as apoptosis depending on the specific genetic context. In p53 
deficient mice, BAX can accelerate tumor growth (Knudson et al., 2001). Our trypan blue 
exclusion assay results, which demonstrated a decrease in cell growth with low 
cytotoxicity (Figure 10), are consistent with BAX as a regulator cell proliferation. Future 
studies may look at the effect of the PPARα antagonist on the ratio of p53: BAX.   
 
We observed cell cycle arrest at G0/G1 in both macrophages and tumor cells. To provide 
evidence for a molecular mechanism, we next examined the protein level of p27, a known 
checkpoint inhibitor between G1 and S. Surprisingly, our western blot analysis 
demonstrated that inhibition of PPARα reduced p27 expression. p27 function may 
depend on its cellular localization (Coqueret, 2003). Recently, it was observed 
cytoplasmic p27 is oncogenic in vitro and in vivo (Serres et al., 2011). Future studies will 
be required to determine the change in the ratio of p27 in the nucleus and cytoplasm in 
response to PPARα inhibition, as well as examining other G0/G1 cell cycle markers. 
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The senescence phenotype is characterized as a stable state of cell arrest. PPARα 
inhibition induced cellular senescence in tumor cells, as shown in Figure 16. The clinical 
relevance of therapy-induced senescence remains poorly characterized. Senescent cells 
can secrete cytokines that can either induce a pro-inflammatory and pro-tumorigenic 
state, or possess anti-tumorigenic activity by initiating the clearance of senescent cells 
through an immune response (Perez-Mancera, Young, & Narita, 2014). Future 
experiments are needed to fully characterize the effect of the PPARα antagonist on tumor 
cells in the context of senescence.   
 
To our knowledge, PPARα inhibition is a novel approach in cancer progression, and only 
recently has PPARα antagonists been studied for its anti-tumor activity. GW6471, a 
different PPARα, has been shown to inhibit renal cell carcinoma, also by inducing cell 
cycle arrest and apoptosis, thus partially confirming the results of our study, but 
moreover the role of PPARα as novel therapeutic target (Aboud, Wettersten, & Weiss, 
2013). To further extend the potential of PPARα inhibition in pancreatic cancer, we 
sought to examine the activity of the PPARα antagonist with gemcitabine, the standard of 
care chemotherapy for pancreatic cancer. In mice bearing pancreatic tumors, the 
combination treatment of the PPARα antagonist and gemcitabine inhibited tumor growth 
more than either treatment alone (Supplemental Figure 1). In a murine orthotopic 
pancreatic cancer model, in which pancreatic tumor cells were injected directly in the 
pancreas, the combination treatment prolonged survival over 120 days compared to the 
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control (10 - 20 days) and the PPARα antagonist and gemcitabine treated groups alone 
(25 - 35 days) (Supplemental Figure 2).   
 
Our study provides evidence for the synergistic anti-tumorigenic action of the PPARα 
antagonist and gemcitabine, and the potent suppression of macrophage and pancreatic 
cancer cell growth through PPARα antagonism. The PPARα antagonist exerts its anti-
growth activity by inducing cell cycle arrest at G0/G1 thereby inducing cellular 
senescence without cell death. Our findings provide a mechanism for the anti-tumor 
activity of PPARα inhibition, and the rationale to use PPARα antagonists to complement 
current treatment regimens as novel therapeutic approach to pancreatic cancer.   
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APPENDIX 
 
 
 
Supplemental Figure 1 | PPARα antagonist and gemcitabine potently suppress pancreatic tumor growth 
(Panc0H7).  
Treatment was initiated when subcutaneous tumors were 100 to 200 mm3 in size in immunocompetent mice. The 
PPARα antagonist was compared to gemcitabine (current standard of care chemotherapy), PD1 (checkpoint inhibitor), 
and various combinations. 
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Supplemental Figure 2 | The PPARα antagonist and gemcitabine prolong survival in an orthotopic murine 
pancreatic cancer model.   
Pancreatic tumor cells were injected directly into the pancreas of the mouse and treatment was started after injection.  
Experiment was performed in collaboration with Dr. Diane Bielenberg (Children’s Hospital, Boston, MA).   
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Supplemental Figure 3 | RAW 264.7 Western blot quantification. 
 P-AKT/AKT normalized with control, and AKT, PCNA, BAX normalized to ACTIN.  The results are means +/- SEM 
(n=3); *p< 0.05 
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Supplemental Figure 4 | Panc0H7 Western blot quantification. 
P-AKT/AKT normalized with control, and AKT, PCNA, BAX, and p27 normalized to ACTIN.  The results are means 
+/- SEM (n=3); *p< 0.05 
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Supplemental Figure 5 | BxPC3 Western blot quantification. 
P-AKT/AKT normalized with control, and AKT, PCNA, and BAX normalized to ACTIN.  The results are means +/- 
SEM (n=3); *p< 0.05 
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